NEW YORK (TheStreet) -- RATINGS CHANGES

Aerie Pharmaceuticals (AERI) was upgraded to buy from hold by Canaccord Genuity, which set a 12-month price target of $40. After much anticipation, Aerie's interactions with the Food and Drug Administration have led to the following: 1) allow ROCKET 2's primary endpoint to include patients with a baseline IOP of 25 mmHg or below; and 2) agreement that the company may use a hierarchically-based statistical approach such that the three arms of the trial remain adequately powered (>85%) and no further enrollment is needed. ROCKET 2 is still expected to have results in Q3/15, Canaccord said.

Amedisys (AMED) was upgraded to buy from hold by Jefferies, which set a 12-month price target of $48, saying that the company's new management team brings renewed energy and direction that will reaccelerate organic and M&A-driven growth and drive margin expansion.

BioMarin (BMRN) was downgraded to neutral from outperform by Robert Baird, which cited valuation, based on a 12-month price target of $133.

BP (BP) was downgraded to sector perform from outperform by RBC Capital, which said the downgrade is a valuation call, as the stock has outperformed its peers year-to-date.

Energy Focus (EFOI) was upgraded to hold by TheStreet Ratings team. You can view the full analysis from the report here: EFOI Ratings Report.

Fiserv (FISV) was upgraded to outperform from perform by Oppenheimer, which set a 12-month price target of $95, saying the company can continue to expand margins and return cash to shareholders.

IPC Healthcare (IPCM) was upgraded to buy from hold by Jefferies, which set a 12-month price target of $70, saying the company can see 35% to 40% of Ebitda upside in 2016 from its participation in the new bundled payment program that Medicare has rolled out.

Lightpath Technologies (LPTH) was upgraded to hold by TheStreet Ratings team. You can view the full analysis from the report here: LPTH Ratings Report.

Lumenis (LMNS) was downgraded to hold from buy by Jefferies, which set a 12-month price target of $14. Lumenis is being acquired by investment firm XIO for $510 million, or $14 a share. While the price of the acquisition is below Jefferies' most recent target of $16, the likelihood of a higher offer is low, Jefferies said.

Micron (MU) was upgraded to buy from hold by Topeka Capital, which set a 12-month price target of $34, saying the company can expand margins in the intermediate term.

Public Storage (PSA) was downgraded to hold from buy by Cantor Fitzgerald, which set a 12-month price target of $199.50. The downgrade is driven by valuation (implied cap rate of 4.7% vs. 4.9% and 5.5% for self-storage REITs and REITs, overall, respectively), limited occupancy upside, rent growth expected to be somewhat in-line with the peers, and FFO/share. growth that is expected to lag (6.7% and 6.5% in 2015 and 2016 vs. 13.4% and 12.2% for self-storage peers), Cantor Fitzgerald said.

Sovran Self Storage (SSS) was upgraded to buy from hold by Cantor Fitzgerald, which set a 12-month price target of $102. The upgrade is driven by revised IRR-driven cap rate, operational upside and discounted valuation (Sovran is trading at an implied cap rate of 6.1% vs. 4.9% and 5.5% for self-storage REITs and REITs, overall, respectively), Cantor Fitzgerald said.

If you liked this article you might like

5 'Strong Buy' Stocks From Wall Street's Best-Performing Analysts

5 'Strong Buy' Stocks From Wall Street's Best-Performing Analysts

Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers

Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers

Biotech Movers: Immunomedics, Aerie, Exelixis

Biotech Movers: Immunomedics, Aerie, Exelixis

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views